Clarkston Skin Research

Clarkston, Michigan 48349

0 studies enrolling now · 17 studies all time

What they study most

Actinic Keratosis, Alopecia Areata, Atopic Dermatitis, Atopic Dermatitis Eczema, Chronic Spontaneous Urticaria, Condylomata Acuminata, Dermatitis, Atopic, Inflammatory Acne Vulgaris, Molluscum Contagiosum, Papillomavirus Infections, Plaque Psoriasis, Psoriasis Vulgaris

Studies at this site

• A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata — Completed
• Study to Evaluate Efficacy and Safety of PF-04965842 With or Without Topical Medications in Subjects Aged 12 Years and Older With Moderate to Severe Atopic Dermatitis — Completed
• Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata — Running, not enrolling
• Study to Evaluate Tezepelumab in Adults With Chronic Spontaneous Urticaria — Completed
• Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1) — Completed
• A Trial to Compare the Incidence of Squamous Cell Carcinoma (SCC) and Other Skin Neoplasia on Skin Areas Treated With Ingenol Disoxate Gel or Vehicle Gel for Actinic Keratosis on Face and Chest or Scalp — Stopped early
• A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts — Completed
• Evaluation of the Efficacy and Safety of Lebrikizumab (LY3650150) in Moderate to Severe Atopic Dermatitis — Completed
• Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1) — Completed
• Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Atopic Dermatitis — Completed
• Safety and Efficacy of Lebrikizumab (LY3650150) in Combination With Topical Corticosteroid in Moderate-to-Severe Atopic Dermatitis. — Completed
• JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis — Completed
• A Dose Ranging Placebo-Controlled Double-Blind Study to Evaluate the Safety and Efficacy of Tezepelumab in Atopic Dermatitis — Stopped early
• Cantharidin Application in Molluscum Patients-1 — Completed
• LEO 90100 Twice Weekly Maintenance Regimen for Psoriasis Vulgaris — Completed
• A Study of Ixekizumab (LY2439821) Compared to Guselkumab in Participants With Moderate-to-Severe Plaque Psoriasis — Completed
• Pivotal Study of Sebacia Microparticles in the Treatment of Acne Vulgaris — Completed